MedTrace Logo

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

NCT00995150 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1910

Last updated 2024-08-14

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Conditions

  • Contraception

Interventions

DRUG

LNG20

levonorgestrel-releasing intrauterine system for contraception

DRUG

Mirena

Mirena intrauterine system

Sponsors & Collaborators

  • Medicines360

    lead OTHER

Principal Investigators

  • Andrea Olariu, MD, PhD · COO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2021-10-12
Completion
2021-10-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00995150 on ClinicalTrials.gov